MCAC Advises AMD Manufacturers To Conduct Randomized, Controlled Trials
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers developing treatments for age-related macular degeneration (AMD) should conduct randomized, controlled trials, CMS' Medicare Coverage Advisory Committee recommended at a Nov. 29 meeting in Baltimore
You may also be interested in...
TEC Says More Evidence Is Required To Judge AMD Combination Therapies
More data are needed before healthcare experts can assess the potential benefits of combining new drugs with photodynamic therapy to treat age-related macular degeneration (AMD), according to BlueCross BlueShield Association's Technology Evaluation Center
TEC Says More Evidence Is Required To Judge AMD Combination Therapies
More data are needed before healthcare experts can assess the potential benefits of combining new drugs with photodynamic therapy to treat age-related macular degeneration (AMD), according to BlueCross BlueShield Association's Technology Evaluation Center
MCAC To Weigh Emerging Treatments For Age-Related Macular Degeneration
CMS' Medicare Coverage Advisory Committee will convene Nov. 29 in Baltimore to evaluate the evidence for age-related macular degeneration (AMD) treatments